

GLAXOSMITHKLINE PLC

Form 6-K

April 16, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 16 April 2019

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr B McNamara
 b) Position/status CEO, GSK Consumer Healthcare

c) Initial notification/ amendment Initial notification

Details of the issuer, emission allowance market

2. participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of

3. transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument American Depositary Shares ('ADSs')
 ISIN: US37733W1053

b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 April 2019 on shares held in the Deferred Annual Bonus Plan Post-Tax.

c) Price(s) and volume(s) Price(s) Volume(s)
 \$40.8259 33.216

Aggregated information

d) Aggregated volume n/a (single transaction)

Price

e) Date of the transaction 2019-04-12

f) Place of the transaction New York Stock Exchange
(XNYS)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: April 16, 2019

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc